SCIENTIFIC, CLINICAL AND COMMERCIAL DEVELOPMENT OF RNA THERAPEUTICS AND VACCINES Discover, develop & get to market by assessing new data & case studies from global RNA experts across Oligo-Based..
Unlock Your Hub’s Fullest Potential: Optimize Operations to Enable Seamless Patient Access and Improved Outcomes Problem-solve with key stakeholders to develop innovative solutions and streamline your hub operations to conquer..
Develop a Unified Scientific Voice The Premier Conference on the West Coast for Medical Affairs Professionals The Fierce Medical Affairs Strategic Summit West provides a platform for medical affairs, field medical, and..
Rebuilding: What’s Next for Biotech The Future of Biotech The biotech landscape is rapidly evolving, and with each breakthrough, the question arises: what’s next? Regulatory complexities, changing market dynamics and..
Fierce Diversity, Equity & Inclusion Forum The Fierce Diversity, Equity, and Inclusion Forum is back again this year and better than ever because we are collaborating with our Fierce Healthcare Editorial Team to expand the topics and audience for this exciting program. Together we are tackling the topics that are top-of-mind- and relevant for all biotech, pharmaceutical, medical..
A celebration of the 50 key players, changemakers and innovators across biotech, pharma and healthcare! Celebrating Monumental Impact The Fierce 50 is a groundbreaking project to identify, elevate and celebrate the individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. The Fierce 50 Awards Gala will be..
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS The latest science and research on antibody engineering, design and selection diving into critical topics including Neurodegenerative Diseases, Tumor Microenvironment in Antibody Therapy, Antibody Immune Agonist, Bi-Specifics, ADCs, Protein-Based Degraders, Immuno-oncology, T-Cells, VHH and much more... Register your interest for the 2024..